阿立哌唑辅助治疗抗抑郁药难治性抑郁的最佳剂量:基于系统综述与剂量效应Meta分析的初步发现
该系统综述与剂量效应Meta分析纳入10项随机对照试验共2625例成人抗抑郁药难治性抑郁患者,评估阿立哌唑辅助治疗8周的有效性、耐受性与可接受性。最大目标剂量-有效性曲线在2mg(OR=1.46,95%CI 1.15-1.85)至5mg(OR=1.93,95%CI 1.33-2.81)间上升,至20mg(OR=1.90,95%CI 1.52-2.37)呈非上升趋势;可接受性无显著差异。作者结论认为低剂量阿立哌唑辅助治疗可能在急性期达到最佳平衡,但纳入研究少且偏倚风险中至高,需进一步研究。
要点
- 10项随机对照试验共2625例成人抗抑郁药难治性抑郁患者纳入分析。
- 有效性在阿立哌唑2mg(OR=1.46)至5mg(OR=1.93)间上升,至20mg(OR=1.90)呈非上升趋势。
- 可接受性在 examined 剂量范围内无显著差异,证据确定性低至中等。
核心结论
- 低剂量阿立哌唑辅助治疗可能在抗抑郁药难治性抑郁的急性期治疗中达到有效性、耐受性与可接受性的最佳平衡。
- 纳入研究数量少且总体偏倚风险中至高,严重损害结果可靠性,需进一步研究比较低剂量与高剂量的获益。
研究设计与样本
- 系统综述与剂量效应Meta分析,检索多个电子数据库(从建库至2021年2月16日)。
- 纳入评估者设盲的随机对照试验,对象为≥18岁、男女不限、至少一种抗抑郁药治疗反应不足的重性抑郁障碍成人。
- 采用随机效应一阶段剂量效应Meta分析,使用限制性立方样条。
- 共10项研究符合纳入标准,均为个体随机、安慰剂对照、多中心、平行研究,共2625例参与者。
主要发现
- 治疗8周(范围4-12周)后有效性(治疗反应:抑郁严重度降低≥50%)的最大目标剂量-有效性曲线在2mg(OR=1.46,95%CI 1.15-1.85)至5mg(OR=1.93,95%CI 1.33-2.81)间上升。
- 有效性曲线在5mg以上至获批剂量上限20mg(OR=1.90,95%CI 1.52-2.37)呈非上升趋势。
- 耐受性(因不良反应脱落)呈相似趋势但不确定性更大。
- 可接受性(任何原因脱落)在所考察剂量范围内无显著差异。
- 证据确定性为低至中等。
关键数值与推荐
- 有效性在阿立哌唑2mg时OR=1.46(95%CI 1.15-1.85),5mg时OR=1.93(95%CI 1.33-2.81),20mg时OR=1.90(95%CI 1.52-2.37)。
- 可接受性在所考察剂量范围内无显著差异。
- 证据确定性为低至中等。
临床怎么用
- 作者结论认为低剂量阿立哌唑辅助治疗可能在抗抑郁药难治性抑郁的急性期治疗中达到有效性、耐受性与可接受性的最佳平衡。
- 作者指出纳入研究数量少且总体偏倚风险中至高,严重损害结果可靠性,需进一步研究比较低剂量与高剂量的获益。
局限性
- 纳入研究数量少。
- 总体偏倚风险中至高,严重损害结果可靠性。
- 需进一步研究比较低剂量与高剂量的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear. AIMS: To find the optimal dosage of aripiprazole augmentation. METHOD: Multiple electronic databases were searched (from inception to 16 February 2021) to identify all assessor-masked randomised controlled trials evaluating aripiprazole augmentation therapy in adults (≥18 years old, both genders) with major depressive disorder showing inadequate response to at least one antidepressant treatment. A random-effects, one-stage dose-effect meta-analysis with restricted cubic splines was conducted. Outcomes were efficacy (treatment response: ≥50% reduction in depression severity), tolerability (drop-out due to adverse effects) and acceptability (drop-out for any reason) after 8 weeks of treatment (range 4-12 weeks). RESULTS: Ten studies met the inclusion criteria. All were individually randomised, placebo-controlled, multi-centre, parallel studies including 2625 participants in total. The maximum target dose-efficacy curve showed an increase up to doses between 2 mg (odds ratio OR = 1.46, 95% CI 1.15-1.85) and 5 mg (OR = 1.93, 95% CI 1.33-2.81), and then a non-increasing trend through the higher licensed doses up to 20 mg (OR = 1.90, 95% CI 1.52-2.37). Tolerability showed a similar trend with greater uncertainty. Acceptability showed no significant difference through the examined dose range. Certainty of evidence was low to moderate. CONCLUSIONS: Low-dose aripiprazole as augmentation treatment might achieve the optimal balance between efficacy, tolerability and acceptability in the acute treatment of antidepressant-refractory depression. However, the small number of included studies and the overall moderate to high risk of bias seriously compromise the reliability of the results. Further research is required to investigate the benefits of low versus high dose.
引用
- Furukawa Y, Hamza T, Cipriani A, et al. Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis. Br J Psychiatry. 2022. PMID: 35049482. doi:10.1192/bjp.2021.165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。